Characteristics of Submucous Myomas and the Risk of Anemia

Background and Objectives: Uterine fibroids still represent the most common indication for hysterectomy for benign pathologies. In the United States, more than 479,000 hysterectomies are performed annually, 46.6% for myomas and 47.7% in women aged from 18 to 44 years. By applying appropriateness criteria to this procedure, it has been estimated that overuse ranges from 16 to 70%. One of the main reasons that induce patients and gynecologists to consider hysterectomy is represented by severe anemia. Materials and Methods: This is a retrospective cohort study of 202 patients with uterine fibroids diagnosed by transvaginal ultrasound who underwent a hysteroscopic procedure. Myoma grade, size, location, and number were assessed by transvaginal scan and office hysteroscopy and correlated to the pre-treatment hemoglobin level. Results: Univariate analysis showed that anemia does not have a statistically significant association with myoma number and with age considered as a numerical predictor. In the patients with myoma type 0, there is a possibility of 81% having anemia regardless of menorrhagia. On the contrary, in patients with myoma type 1 or type 2, the possibility of having anemia varies according to the presence or absence of menorrhagia. If there is menorrhagia, the risk of moderate anemia is only present for myomas >60 mm. Conclusions: The results of this study may contribute to defining objective criteria for the management of submucous myomas and anemia. Our data suggest that submucosal myomas type 0 >10 mm should always be treated, putting patients at risk for anemia. Myomas type 2 and 3 should be treated for the risk of anemia in the presence of menorrhagia episodes or if > of 60 mm. Adequate management of anemia and myomas could reduce the rate of unnecessary hysterectomies.

[1]  S. Quinn,et al.  Appraisal of national and international uterine fibroid management guidelines: a systematic review. , 2021, BJOG : an international journal of obstetrics and gynaecology.

[2]  Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228. , 2021, Obstetrics and gynecology.

[3]  Mostafa A Borahay,et al.  The Future of Uterine Fibroid Management: a More Preventive and Personalized Paradigm , 2021, Reproductive Sciences.

[4]  G. Ricci,et al.  Cotyledonoid Leiomyoma Clinical Characteristics, Imaging Features, and Review of the Literature , 2020, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[5]  G. Ricci,et al.  Ectopic Cervical Pregnancy: Treatment Route , 2020, Medicina.

[6]  Jennifer E. Moore,et al.  Agency for Healthcare Research and Quality , 2020, Definitions.

[7]  S. As-Sanie,et al.  Epidemiology and management of uterine fibroids , 2020, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[8]  C. Allaire,et al.  Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas - An Addendum. , 2019, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[9]  P. Suchdev,et al.  Anemia epidemiology, pathophysiology, and etiology in low‐ and middle‐income countries , 2019, Annals of the New York Academy of Sciences.

[10]  G. Ricci,et al.  Phosphoproteins Involved in the Inhibition of Apoptosis and in Cell Survival in the Leiomyoma , 2019, Journal of clinical medicine.

[11]  J. Cavanaugh,et al.  The Akaike information criterion: Background, derivation, properties, application, interpretation, and refinements , 2019, WIREs Computational Statistics.

[12]  E. Stewart,et al.  Moving Toward Individualized Medicine for Uterine Leiomyomas. , 2018, Obstetrics and gynecology.

[13]  A. Mas,et al.  Updated approaches for management of uterine fibroids , 2017, International journal of women's health.

[14]  R. Lasmar,et al.  The role of leiomyomas in the genesis of abnormal uterine bleeding (AUB). , 2017, Best practice & research. Clinical obstetrics & gynaecology.

[15]  E. Buchanan,et al.  Uterine Fibroids: Diagnosis and Treatment. , 2017, American family physician.

[16]  T. Rabe,et al.  Symptoms of uterine myomas: data of an epidemiological study in Germany , 2017, Archives of Gynecology and Obstetrics.

[17]  L. Wise,et al.  Epidemiology of Uterine Fibroids: From Menarche to Menopause. , 2016, Clinical obstetrics and gynecology.

[18]  E. Sarıdoğan Surgical Treatment of Fibroids in Heavy Menstrual Bleeding , 2016, Women's health.

[19]  Eva van der Meij,et al.  Hysterectomy for Heavy Menstrual Bleeding , 2016, Women's health.

[20]  D. Campbell,et al.  Use of other treatments before hysterectomy for benign conditions in a statewide hospital collaborative. , 2015, American journal of obstetrics and gynecology.

[21]  Jon I. Einarsson,et al.  Updated Hysterectomy Surveillance and Factors Associated With Minimally Invasive Hysterectomy , 2014, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

[22]  P. Erwin,et al.  Submucosal fibroids and the relation to heavy menstrual bleeding and anemia. , 2014, American journal of obstetrics and gynecology.

[23]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[24]  Suzanne L Palmer,et al.  Sensitivity of myoma imaging using laparoscopic ultrasound compared with magnetic resonance imaging and transvaginal ultrasound. , 2013, Journal of minimally invasive gynecology.

[25]  S. Bendifallah,et al.  Therapeutic management of uterine fibroid tumors: updated French guidelines. , 2012, European journal of obstetrics, gynecology, and reproductive biology.

[26]  E. Henry,et al.  The Effect of Preoperative Checklists on Final Histology and Rates of Hysterectomy for Benign Conditions , 2012, Female pelvic medicine & reconstructive surgery.

[27]  P. Shekelle,et al.  Appropriateness criteria to assess variations in surgical procedure use in the United States. , 2011, Archives of surgery.

[28]  C. Ananth,et al.  Uterine fibroids: Correlations of anemia and pain to fibroid location and uterine weight. , 2011, The Journal of reproductive medicine.

[29]  Chi-Ling Chen,et al.  Impact of submucous myoma on the severity of anemia. , 2011, Fertility and sterility.

[30]  E. McLean,et al.  Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005 , 2009, Public Health Nutrition.

[31]  B. V. Van Voorhis A 41-year-old woman with menorrhagia, anemia, and fibroids: review of treatment of uterine fibroids. , 2009, JAMA.

[32]  K. Hornik,et al.  Unbiased Recursive Partitioning: A Conditional Inference Framework , 2006 .

[33]  P. Vercellini,et al.  Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. , 2004, Human reproduction.

[34]  Irva Hertz-Picciotto,et al.  Self‐Reported Heavy Bleeding Associated With Uterine Leiomyomata , 2003, Obstetrics and gynecology.

[35]  K Wamsteker,et al.  Transcervical Hysteroscopic Resection of Submucous Fibroids for Abnormal Uterine Bleeding: Results Regarding the Degree of Intramural Extension , 1993, Obstetrics and gynecology.

[36]  R. Farquharson,et al.  Management of uterine fibroids. , 1993, British journal of hospital medicine.

[37]  A. Patel,et al.  The frequency of uterine leiomyomas. , 1990, American journal of clinical pathology.

[38]  H. Akaike A new look at the statistical model identification , 1974 .